aflitzy

Four Biotech Stocks to Play the Sector Pullback

CEL-SCI's L.E.A.P.S.(TM) H1N1 Flu Development Seen as Credibility Booster
12:34 pm ET 11/06/2009- Business Wire
LOS ANGELES--(BUSINESS WIRE)--

BioMedReports.com, the news portal which covers Wall Street's biomedical

sector and delivers financial and investment intelligence to a community

of highly informed investors, reports that one of several expected key

news developments has been announced by CEL-SCI Corporation (NYSE Amex:

CVM), today.


An Institutional Review Board of The Johns Hopkins University School of

Medicine (Johns Hopkins) has given clearance for the Company's first

clinical study involving the much talked about L.E.A.P.S.(TM) H1N1

investigational therapy.


The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical

development program builds on CEL-SCI's pioneering work with its

L.E.A.P.S.(TM) technology, whose reach goes beyond the H1N1 space, and

whose responses can be designed to be directed at a great number of

human diseases.


Investors, who have sent the stock price up on the news, apparently also

view the news as a much needed credibility boost in light of recent

attacks by a single columnist against the company. Despite those

published attacks, shares of the company have risen dramatically in the

past few months and many expect that trend to continue as the company

moves forward on several fronts, including a pending, and long

anticipated launch of Phase III trials for Multikine(R), CEL-SCI's

flagship cancer immunotherapeutic agent, which is being developed as a

first-line standard of care cancer treatment.


The complete report is available now at BioMedReports.com:


biomedreports.com/arti...